Want to track TLTFF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Theralase narrows Q1 loss as it advances bladder cancer trial
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) continued to advance its lead asset, bladder cancer treatment Rudivar, in the first quarter of 2024. The firm is evaluating Rudivar activated by a proprietary device in the Study II clinical trial, which is focused on enrolling and treating approximately 100 patients with Bacillus Calmette Guerin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS).
Proactiveinvestors | 2 years ago
